Status:
COMPLETED
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
Lead Sponsor:
Sun Yat-sen University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
Brief Summary
A novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dMMR colon cancer was developed to validated its efficacy ...
Detailed Description
Immunotherapy shows promise as a curative treatment for patients with non-metastatic dMMR CRC, and offers an option of watch-and-wait (W\&W) strategy for those achieving clinical complete response (cC...
Eligibility Criteria
Inclusion
- pathologically confirmed colon adenocarcinoma;
- immunohistochemistry testing as dMMR tumors;
- received at least two doses of anti-PD-1 immunotherapy in a neoadjuvant setting.
- received radical surgery.
Exclusion
- \-
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT06980350
Start Date
July 1 2018
End Date
December 30 2024
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060